Skip to content

Effect of resveratrol on periodontal disease treatment of smokers.

Effect of resveratrol on non-surgical periodontal treatment of smokers diagnosed with Chronic Periodontitis. Prospective evaluation of clinical, microbiological, immunological results and quantification of neutrophils.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3gt65c
Enrollment
Unknown
Registered
2020-03-03
Start date
2015-01-11
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal diseases, smokers

Interventions

Groups: Control - twenty patients (womand or man) will receive ultrasonic debridement of the entire mouth in a single session, associated with systemic administration of placebo, for 360 days
Test - twenty patients (womand or man) will receive ultrasonic debridement of the entire mouth in a single session, associated with the systemic administration of 500 mg of resveratrol for 360 days. R
Dietary supplement
G07.203.300.456

Sponsors

Universidade Paulista
Lead Sponsor
Universidade Paulista
Collaborator

Eligibility

Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnosis of generalized chronic periodontitis with at least 8 teeth with Probing Depth (PD) and Clinical Attachment Level (CAL) equal to or above 5 mm and Bleeding on Probing. Of these 8 teeth chosen, at least two teeth should present PD and CAL equal to or above 7 mm; Presence of at least 20 teeth in the oral cavity;Smoking cigarette for at least 5 years and at least 10 cigarettes per day.

Exclusion criteria

Exclusion criteria: Periodontal treatment in the 6 months prior to the study; Use of medications, such as antibiotics, continuous anti-inflammatories, phenytoin, cyclosporine, in the 6 months prior to the study; Presence of systemic changes or active infectious disease (diabetes, heart disease, hepatitis, etc.); Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frame
It is expected a gain in clinical attachment level and a reduction in probing depthin the group treated with resveratrol compared to the placebo group, by means of clinical measurement OF clinical attachement level and of probing pocket depth using a periodontal probe

Secondary

MeasureTime frame
It is expected reduction in the production of pro-inflammatory factors and increase in the production of anti-inflammatory factors in the group treated with resveratrol compared to the placebo group, through the quantification of inflammatory factors, using the immunoenzimatic assay.

Countries

Brazil

Contacts

Public ContactAna Paula Bossolan

Universidade Paulista

anagetti@hotmail.com+55 11 997994849

Outcome results

None listed

Source: REBEC (via WHO ICTRP)